Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker? Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
The diagnostic value of serum tumor markers in newly diagnosed lung cancer patients Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Analysis of surgical stage lung cancer and tumour markers prognostic value Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Are there any peculiarities in tumour behavior and different tumour markers expression in nonsmall cell lung cancer? Source: Eur Respir J 2001; 18: Suppl. 33, 232s Year: 2001
Serum angiopoietins as a clinical marker for resected early lung cancer Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
The detection of quantitative serum p53 protein in lung cancer and its clinical value Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Different profile of hyaluronidase expression is associated with histological types and prognosis in lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
The correlation of serum tumor markers and distant metastasis in lung adenocarcinoma Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer Source: Eur Respir J 2015; 46: 1773-1780 Year: 2015
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
A novel serum biomarker of type XXVIII collagen turnover is elevated in lung cancer but not in COPD Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Chemerin and PAI-1 activity as diagnostic biomarkers in resectable NSCLC:comparison to classic tumour markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019
Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008